Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006, 150(1):5-12 | DOI: 10.5507/bp.2006.001

EFFECTS OF SANGUINARINE AND CHELERYTHRINE ON THE CELL CYCLE AND APOPTOSIS

Jana Malikovaa, Adela Zdarilovab, Alice Hlobilkovaa
a Laboratory of Molecular Pathology and Institute of Pathology, Faculty of Medicine, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic
b Institute of Medical Chemistry and Biochemistry, Faculty of Medicine, Palacký University, Hněvotínská 3, 775 15 Olomouc, Czech Republic

OBJECTIVES: This review summarizes the involvement of sanguinarine and chelerythrine in cell cycle regulation and cell death in various cell lines. It is focused on their potential in the treatment of cancer.

METHODS: We conducted a search of PubMed, ScienceDirect and Medline for papers on the molecular mechanisms of the biological activity of sanguinarine and chelerythrine published mainly from 1995 to 2006.

RESULTS AND CONCLUSIONS: Our analysis of the published studies suggested that these alkaloids are not only good candidates for chemotherapeutic regimens but may also contribute to the development of successful immune therapies of some carcinomas due to their apoptotic potential. However, the complete signalling cascade in which sanguinarine and chelerythrine treatment induces apoptotic cell death is not yet understood. Overall, the results of recent studies suggest that sanguinarine and chelerythrine may be useful as agents in the management of cancer.

Keywords: Quaternary benzo[c]phenanthridine alkaloids, Cytotoxicity, Apoptosis, Cancer, Cell signalling, Proliferation

Received: April 15, 2006; Accepted: June 5, 2006; Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malikova, J., Zdarilova, A., & Hlobilkova, A. (2006). EFFECTS OF SANGUINARINE AND CHELERYTHRINE ON THE CELL CYCLE AND APOPTOSIS. Biomedical papers150(1), 5-12. doi: 10.5507/bp.2006.001
Download citation

References

  1. Zdarilova A, Malikova J, Dvorak Z, Ulrichova J, Simanek V. Quaternary isoquinoline alkaloids sanguinarine and chelerythrine. In vitro and in vivo effects. Chem. Listy 2006; 100: 30-41.
  2. Walterova D, Ulrichova J, Valka I, Vicar J, Vavreckova C, Taborska E, Harjrader RJ, Meyer DL, Cerna H, Simanek V. Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Acta Univ Palacki Olomuc Fac Med 1995; 139: 71-6.
  3. Slaninova I, Taborska E, Bochorakova H, Slanina J. Interaction of benzo[c]phenanthridine and protoberberine alkaloids with animal and yeast cells. Cell Biol Toxicol 2001; 17: 51-63. Go to original source... Go to PubMed...
  4. Walterova D, Ulrichova, Preininger V, Simanek V, Lenfeld J, Lasovsky J. Inhibition of liver alanine aminotransferase activity by some benzophenanthridine alkaloids. J Med Chem 1981; 24: 1100-1103. Go to original source... Go to PubMed...
  5. Bartak P, Vlckova M, Ulrichova J, Simanek V, Vespalec R. Interactions of sanguinarine and chelerythrine with molecules containing the mercapto group. J Phys Org Chem 2003; 16: 803-810. Go to original source...
  6. Ulrichova J, Dvorak Z, Vicar J, Lata J, Smrzova J, Sedo A, Simanek V. Cytotoxicity of natural compounds in hepatocyte cell culture models. The case of quaternary benzo[c]phenanthridine alkaloids. Toxicol Lett 2001; 125: 125-132. Go to original source... Go to PubMed...
  7. Stiborova M, Simanek V, Frei E, Hobza P, Ulrichova J. DNA adduct formation from quaternary benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine as revealed by the P-32- postlabeling technique. Chem Biol Interact 2002; 140: 231-242. Go to original source... Go to PubMed...
  8. Faddeeva MD, Beliaeva TN. Sanguinarine and ellipticine cytotoxic alkaloids isolated from well-known antitumor plants. Intracellular targets of their action. Tsitologiia 1997; 39: 181-208. Go to PubMed...
  9. Das M, Khanna SK. Clinicoepidemiological, toxicological, and safety evaluation studies on argemone oil. Crit Rev Toxicol 1997; 27: 273-297. Go to original source... Go to PubMed...
  10. Simanek V, Vespalec R, Sedo A., Ulrichova J, Vicar J. Quaternary benzo[c]phenanthridine alkaloids - Biological activities. Chemical Probes in Biology. NATO Science Series 2003; 129: 145-154. Go to original source...
  11. Malikova J, Zdarilova A, Hlobilkova A, Ulrichova J. Effects of quaternary benzo[c]phenanthridine alkaloids on human normal versus cancer cells., unpublished results. 2006
  12. Das M, Ansari KM, Dhawan A, Shukla Y, Khanna SK. Correlation of DNA damage in epidemic dropsy patients to carcinogenic potential of argemone oil and isolated sanguinarine alkaloid in mice. Int J Cancer 2005; 117: 709-717. Go to original source... Go to PubMed...
  13. Ansari KM, Dhawan A, Khanna SK, Das M. In vivo DNA damaging potential of sanguinarine alkaloid, isolated from argemone oil, using alkaline Comet assay in mice. Food Chem Toxicol 2005; 43: 147-153. Go to original source... Go to PubMed...
  14. Ansari KM, Dhawan A, Khanna SK, Das M. Protective effect of bioantioxidants on argemone oil/sanguinarine alkaloid induced genotoxicity in mice. Cancer Lett 2006; [Epub ahead of print]. Go to original source... Go to PubMed...
  15. Hakim SA, Mijovic V, Walker J. Experimental transmission of sanguinarine in milk: detection of a metabolic product. Nature 1961; 189: 201-204. Go to original source... Go to PubMed...
  16. Tandon S, Das M, Khanna SK. Biometabolic elimination and organ retention profile of argemone alkaloid, sanguinarine, in rats and guinea pigs. Drug Metab Dispos 1993; 21: 194-197.
  17. Psotova J, Klejdus B, Vecera R, Kosina P, Kuban V, Vicar J, Simanek V, Ulrichova J. A liquid chromatographic-mass spectrometric evidence of dihydrosanguinarine as a first metabolite of sanguinarine transformation in rat. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 165-172. Go to original source... Go to PubMed...
  18. Weiss D, Baumert A, Vogel M, Roos W. Sanguinarine reductase, a key enzyme of benzophenanthridine detoxification. Plant Cell Environ 2006; 29: 291-302. Go to original source... Go to PubMed...
  19. Hodgson E, Levi PE. Introduction to biochemical toxicology. Appelton&Lange, Norwalk 1994 219-240.
  20. Vecera R, Klejdus B, Kosina P, Orolin J, Stiborova M, Smrcek S, Vicar J, Dvorak Z, Ulrichova J, Kuban V, Anzenbacher P, Simanek V. Disposition of sanguinarine in rat. Drug Metab Dispos 2006, accepted. Go to original source...
  21. Belyaeva T, Leontieva E, Shpakov A, Mozhenok T, Faddejeva M. Sensitivity of lysosomal enzymes to the plant alkaloid sanguinarine: comparison with other SH-specific agents. Cell Biol Int 2003; 27: 887-895. Go to original source... Go to PubMed...
  22. Adhami VM, Aziz MH, Reagan-Shaw SR, Nihal M, Mukhtar H, Ahmad N. Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. Mol. Cancer Ther. 2004; 3: 933-940. Go to original source...
  23. Chmura SJ, Dolan ME, Cha A, Mauceri HJ, Kufe DW, Weichselbaum RR. In vitro and in vivo activity of protein kinase C inhibitor chelerythrine chloride induces tumor cell toxicity and growth delay in vivo. Clin Cancer Res 2000; 6: 737-742.
  24. Ahmad N, Gupta S, Husain MM, Heiskanen KM, Mukhtar H. Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells. Clin Cancer Res 2000; 6: 1524-1528.
  25. Adhami VM, Aziz MH, Mukhtar H, Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res 2003; 9: 3176-3182.
  26. Kasibhatla S, Tseng B. Why target apoptosis in cancer treatment? Mol Cancer Ther 2003; 2: 573-580.
  27. Wyllie AH. Apoptosis and carcinogenesis. Eur J Cell Biol 1997; 73: 189-197.
  28. Orrenius S. Apoptosis: molecular mechanisms and implications for human disease. J Intern Med 1995; 237: 529-536. Go to original source... Go to PubMed...
  29. McConkey DJ, Zhivotovsky B, Orrenius S. Apoptosis-- molecular mechanisms and biomedical implications. Mol Aspects Med 1996; 17: 1110. Go to original source... Go to PubMed...
  30. Tapia-Vieyra JV, Mas-Oliva J. Apoptosis and cell death channels in prostate cancer. Arch Med Res 2001; 32: 175-185. Go to original source... Go to PubMed...
  31. Collins JA, Schandi CA, Young KK, Vesely J, C. WM. Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 1997; 45: 923-934. Go to original source... Go to PubMed...
  32. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002; 31: 214-223. Go to original source... Go to PubMed...
  33. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000; 21: 485-495. Go to original source... Go to PubMed...
  34. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991; 64: 192-196. Go to original source... Go to PubMed...
  35. Huh J, Liepins A, Zielonka J, Andrekopoulos C, Kalyanaraman B, Sorokin A. Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity. Cancer Res 2006; 66: 3726-3736. Go to original source... Go to PubMed...
  36. Debiton E, Madelmont JC, Legault J, Barthomeuf C. Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion. Cancer Chemother. Pharmacol 2003; 51: 474-482. Go to original source... Go to PubMed...
  37. Holy J, Lamont G, Perkins E. Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine. BMC Cell Biol 2006; 7: 13. Go to original source... Go to PubMed...
  38. Ding ZH, Tang SC, Weerasinghe P, Yang XL, Pater A, Liepins A. The alkaloid sanguinarine is effective against multidrug resistance in human cervical cells via bimodal cell death. Biochem Pharmacol 2002; 63: 1415-1421. Go to original source... Go to PubMed...
  39. Kemeny-Beke A, Aradi J, Damjanovich J, Beck Z, Facsko A, Berta A, Bodnar A. Apoptotic response of uveal melanoma cells upon treatment with chelidonine, sanguinarine and chelerythrine. Cancer Lett 2005; 237: 67-75. Go to original source... Go to PubMed...
  40. Weerasinghe P, Hallock S, Tang SC, Liepins A. Role of Bcl- 2 family proteins and caspase-3 in sanguinarine-induced bimodal cell death. Cell Biol Toxicol 2001; 17: 371-381. Go to original source... Go to PubMed...
  41. Weerasinghe P, Hallock S, Tang SC, Liepins A. Sanguinarine induces bimodal cell death in K562 but not in high Bcl-2-expressing JM1 cells. Pathol Res Pract 2001; 197: 717-726. Go to original source... Go to PubMed...
  42. Weerasinghe P, Hallock S, Liepins A. Bax, Bcl-2, and NFkappa B expression in sanguinarine induced bimodal cell death. Exp Mol Pathol 2001; 71: 89-98. Go to original source... Go to PubMed...
  43. Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 2003; 278: 20453-20456. Go to original source... Go to PubMed...
  44. Yamamoto S, Seta K, Morisco C, Vatner SF, Sadoshima J. Chelerythrine rapidly induces apoptosis through generation of reactive oxygen species in cardiac myocytes. J Mol Cell Cardiol 2001; 33: 1829-1848. Go to original source... Go to PubMed...
  45. Launay S, Hermine O, Fontenay M, Kroemer G, Solary E, Garrido C. Vital functions for lethal caspases. Oncogene 2005; 24: 5137-5148. Go to original source... Go to PubMed...
  46. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281: 1312-1316. Go to original source... Go to PubMed...
  47. Mancini M, Nicholson DW, Roy S, Thornberry NA, Peterson EP, Casciola-Rosen LA, Rosen A. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J Cell Biol 1998; 140: 1485-1495. Go to original source... Go to PubMed...
  48. Hajra KM, Liu JR. Apoptosome dysfunction in human cancer. Apoptosis 2004; 9: 691-704. Go to original source... Go to PubMed...
  49. Herbert JM, Augereau JM, Gleye J, Maffrand JP. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1990; 172: 993-999. Go to original source... Go to PubMed...
  50. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, Lazo JS. The benzo[c] phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 2005; 280: 19078-19086. Go to original source... Go to PubMed...
  51. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512. Go to original source... Go to PubMed...
  52. Coqueret O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13: 65-70. Go to original source... Go to PubMed...
  53. Lopus M, Panda D. The benzophenanthridine alkaloid sanguinarine perturbs microtubule assembly dynamics through tubulin binding. Febs J 2006; 273: 2139-2150. Go to original source... Go to PubMed...
  54. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488. Go to original source...
  55. Maldonado V, Melendez-Zajgla J, Ortega A. Modulation of NF-kappa B, and Bcl-2 in apoptosis induced by cisplatin in HeLa cells. Mutat Res 1997; 381: 67-75. Go to original source... Go to PubMed...
  56. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683. Go to original source... Go to PubMed...
  57. Chaturvedi MM, Kumar A, Darnay BG, Chainy GBN, Agarwal S, Aggarwal BB. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-kappa B activation, I kappa B alpha phosphorylation, and degradation. J Biol Chem 1997; 272: 30129-30134. Go to original source... Go to PubMed...
  58. von Harsdorf R., Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99: 2934-2941. Go to original source... Go to PubMed...